Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the signing of new distribution partnerships for its ViroCAP® product in six additional markets. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, significantly broadening the company's international footprint. Each partnership is with a separate company and pertains to an individual market, with minimum purchase quantities agreed upon. Based on these contracts, Viromed anticipates additional sales of at least 3,000 devices per year.
ViroCAP® is a mobile medical device designed for the treatment of skin conditions using cold atmospheric plasma. It is intended for use by hospitals, private practice physicians, and surgically active medical specialists. The device represents a pioneering application of cold plasma technology in medical settings.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, commented: "With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks."
This expansion aligns with Viromed's strategy to grow its international distribution network. The company already has numerous distribution and marketing partnerships in place, including an exclusive distribution agreement with the Korean company UMECO covering ten Asian countries, and a distribution partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. These partnerships are part of Viromed's broader efforts to establish a strong global presence for its innovative cold plasma technology.
The significance of these new agreements lies in Viromed's ability to penetrate diverse and growing healthcare markets. Southern Europe, the Balkans, and the Middle East present opportunities for advanced medical devices, particularly in dermatology and surgical specialties. By securing partnerships in these regions, Viromed not only diversifies its revenue streams but also increases the accessibility of ViroCAP® to a wider patient population. The minimum purchase commitments provide a stable revenue baseline and demonstrate the partners' confidence in the product's market potential.
Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the development, manufacture, and distribution of medical products, with a particular emphasis on cold plasma technology. The company operates through its wholly owned subsidiary Viromed Medical GmbH and has built a broad customer base in the DACH region and beyond. The company's goal is to further advance the use of cold plasma in medicine, and these new partnerships represent a concrete step toward achieving that objective.
As Viromed continues to expand its distribution network, the company is poised to capitalize on the growing demand for non-invasive and effective treatment options in dermatology. The new agreements are expected to contribute significantly to the company's growth trajectory, with additional partnerships anticipated in the near future. The company's proactive approach to international expansion underscores its commitment to becoming a leading player in the medical cold plasma sector.
